Radiologic imaging of muscle tissue is increasingly being used as a tool to aid diagnosis of neuromuscular diseases. A review from the University…
Magdalena Kegel
Magdalena is a writer with a passion for bridging the gap between the people performing research, and those who want or need to understand it. She writes about medical science and drug discovery. She holds an MS in Pharmaceutical Bioscience and a PhD — spanning the fields of psychiatry, immunology, and neuropharmacology — from Karolinska Institutet in Sweden.
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.
Articles by Magdalena Kegel
Numerous studies show that deflazacort substantially prolongs walking ability in boys with Duchenne muscular dystrophy (DMD), allowing them to lead…
The second annual Napa in Newport drew more than 420 guests in a sold-out event that raised more than $700,000 to help…
Scientists have discovered why fetal muscle stem cells are better at regenerating muscle than adult muscle stem cells. These findings open…
The Precision Medicine Initiative was launched in 2015 to spur biomedical research and the development of a more personalized approach to…
Pfizer, in collaboration with Newcastle University, reports finding four serum biomarkers for three types of muscular dystrophy. The markers may…
UCLA scientists have developed a potential gene therapy approach for Duchenne muscular dystrophy (DMD) using CRISPR/Cas9 technology and stem cells. If the new treatment proves…
Scientists Aim for Better Treatments for Muscular Dystrophies in New Discovery of Protein Complex
A discovery clears up the confusion about the molecular factors involved in muscle repair. The research, published in the journal…
Catabasis Pharmaceuticals announced it will present data on CAT-1004 at the XIV International Conference on Duchenne and Becker Muscular Dystrophy to be…
Sarepta Therapeutics, a developer of RNA-targeted treatments, announced that the U.S. Food and Drug Administration (FDA) is extending by another three…